NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024

NewAmsterdam Pharma Co N.V.

2023-FY EPS reported -$2.15 revenue$14,090,000

FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.
Cash at Dec 31, 2023: $340.5M; proforma cash after Feb 2024 $202M upsized offering ~$500M.
Phase 3 BROOKLYN topline in HeFH expected 3Q2024; BROADWAY in ASCVD expected 4Q2024.
PREVAIL CVOT enrollment to complete 1Q2024; topline data expected 2026. TANDEM FDC trial initiation 1Q2024 with data 1Q2025.
Appointed William H. Lewis as Board Chair; Phase 2 data showed significant LDL-C lowering with placebo-like safety.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NewAmsterdam Pharma Co N.V. reported financial results for the full year ended December 31, 2023.

Period: the full year ended December 31, 2023
Result: reported results

Exact text from the filing

NewAmsterdam Pharma Company N.V. (the "Company") issued a press release announcing corporate updates and its financial results for the full year ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0001193125-24-049263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.